Skip to main content
. 2016 Oct 10;12(6):4485–4492. doi: 10.3892/ol.2016.5237

Figure 1.

Figure 1.

Increased expression of UBE2T in human bladder cancer tissues and cell lines. (A) Representative immunohistochemical staining of UBE2T in normal control tissues and bladder cancer tissues (magnification, ×200; scale bar, 50 µm): (a) Negative or weak UBE2T expression in normal bladder tissues; (b) strong expression of UBE2T in transitional cell carcinoma of the bladder; (c) strong expression of UBE2T in squamous cell carcinoma of the bladder. (B) Representative western blots showing the expression of UBE2T in bladder cancer tissues (tumor/T) and tumor-adjacent bladder tissues (normal/N). The relative UBE2T protein expression is expressed as the mean ± standard deviation from 12 cases, with GAPDH serving as a loading control. **P<0.01. (C) Western blots showing the expression of UBE2T in human bladder cancer cell lines. The normal human urinary tract epithelial cell line SV-HUC-1 was used as negative control. GAPDH served as the loading control. The results represent at least three separate experiments. UBE2T, ubiquitin-conjugating enzyme E2T.